Assessing the Benefits of Rosiglitazone in Women With Polycystic Ovary Syndrome through Its Effects on Insulin-Like Growth Factor 1, Insulin-Like Growth Factor-Binding Protein-3 and Insulin Resistance: A Pilot Study. Clinics 2012, 67 (3), 283-287. https://doi.org/10.6061/clinics/2012(03)14.